Company Analysis: Kyowa Kirin

The publisher explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot

Overview - Kyowa Kirin’s late-stage pipeline and exposure to generics mean an increased reliance on new product revenue.
Key themes - [1] Kyowa Kirin revenue continues to be negatively impacted by branded and generic competition to its portfolio of longer-listed products [2] Kyowa Kirin is combating these sales declines and providing Rx sales growth through its new products such as Orkedia, which is a successor to long-listed product Regpara, and finding opportunities elsewhere with a rituximab biosimilar and growth through overseas activity with Crysvita, Poteligeo, and Nouriast.

Model updates (30 October 2020)

Model updates (31 October 2019)

Model updates (14 August 2019)

Crysvita forecast adjusted higher due to strong post-launch results in North America
Orkedia forecast adjusted higher due to strong reported sales growth
Poteligeo forecast adjusted higher due to strong US market penetration from successful launch
Allelock forecast adjusted lower due to increased generic competition
Abstral forecast adjusted lower due to Brexit issues.

Company Background

Company Forecast

Company Profile

Clinical Trial Overview

Table of Contents